Karolinska University Hospital
Stockholm, 14186, Sweden
Location status: Recruiting
NCT Number: NCT04445571
This trial evaluates the efficacy and safety of surfactant administration with thin catheter technique together with analgesic premedication in comparison with the established INSURE-strategy. It will provide valuable knowledge to improve clinical methodology and enhance lung protective treatment strategies for preterm infants.
Interested in participating?
Request InfoUp to 2 day
All sexes
Interventional
Not applicable
Stockholm, 14186, Sweden
Location status: Recruiting
To compare two approaches for surfactant administration during CPAP in preterm infants, the INSURE and the LISA technique, using premedication intubation protocols, and investigate aspects of safety, stress and pain, timely administration of the drug, response in oxygenation and pulmonary outcome.
Our study asks whether (P) among infants born <32 weeks' gestation with RDS (I) does surfactant administration with LISA and analgesia premedication (C) versus surfactant administration according to the INSURE protocol (O) improve oxygenation and reduce the rate of respiratory failure and need for intubation and mechanical ventilation (T) within 48 hours of the procedure
Primary outcomes:
Safety outcomes:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Infants will be excluded from the final analysis if they have a congenital abnormality or condition that might have an adverse effect on breathing or ventilation, including: congenital diaphragmatic hernia; tracheo-oesophageal fistula or cyanotic heart disease.
Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.
Time frame: 24 hours post-procedure
Arterial to alveolar ratio (a/A ratio)
Time frame: 48 hours post-procedure
Need for intubation and mechanical ventilation (MV)
Time frame: Discharge
Duration of MV (hours), CPAP (days), Oxygen (days)
Time frame: Discharge
Incidence of air leaks, bronchopulmonary dysplasia, Systemic hypotension, retinopathy, necrotizing entercolitis, intraventricular hemorrhage, persistent duct
Time frame: Discharge
Death or composite outcome death/BPD
Time frame: Discharge
Number of days in NICU and total in neonatal care, including home care
Time frame: 24 hours
Time from meeting the FiO2 or a/A ratio criteria for surfactant treatment until surfactant administration
Time frame: 24 hours
Number of tries before successful intubation/placement of catheter
Time frame: 24 hours
Positive pressure ventilation during the procedure - yes/no/duration (minutes)
Time frame: 24 hours
Changes in heart rate, blood pressure and BIIP-scales
Contact information is provided by the study sponsor or research team.
Karolinska Institutet
Other
Acronym: SAINT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06554522
Female Urogenital Diseases and Pregnancy Complications, Lung Diseases
Bangui, Central African Republic
View Trial DetailsNCT06917326
Female Urogenital Diseases and Pregnancy Complications, Lung Diseases
Borås, Sweden
View Trial DetailsNCT07060911
Female Urogenital Diseases and Pregnancy Complications, Lung Diseases
Palo Alto, California, United States
View Trial DetailsNCT04542096
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Vilnius, Vilnius County, Lithuania
View Trial Details